Latest Market Expansion News

Eden Innovations has expanded its EdenCrete Pz7 installations across North America, launched a new defence-focused division EdenShield, and eliminated costly debt, positioning for growth with a $4 million capital raise.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Yugo Metals (ASX:YUG) secured government approval for its Petrovo tenement in Bosnia, while initial drilling at Sinjakovo’s Kovacevac and Erak prospects delivered promising polymetallic results. The company also appointed Petar Tomašević as permanent CEO, positioning itself for further exploration progress.

Adveritas Limited surged to $15.08 million ARR, up 91% year-on-year, powered by a new self-serve SME platform and AI-driven product enhancements.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.